105245-87-2 Usage
Uses
Used in Pharmaceutical Industry:
1-(2,5-Dioxo-2,5-dihydro-1H-imidazol-4-yl)urea is utilized as a building block for the synthesis of pharmaceutical compounds due to its ability to be incorporated into drug molecules, thereby modifying their biological properties.
Used in Drug Development:
In the realm of drug development, 1-(2,5-Dioxo-2,5-dihydro-1H-imidazol-4-yl)urea is considered a promising candidate for the creation of new medications, particularly because of its demonstrated potential in antitumor and anti-inflammatory activities, which are crucial for treating various diseases and conditions.
Used in Research:
1-(2,5-Dioxo-2,5-dihydro-1H-imidazol-4-yl)urea is also employed in research settings to explore its potential applications and to understand its mechanisms of action, which can lead to the discovery of new therapeutic agents and treatment strategies.
Check Digit Verification of cas no
The CAS Registry Mumber 105245-87-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,5,2,4 and 5 respectively; the second part has 2 digits, 8 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 105245-87:
(8*1)+(7*0)+(6*5)+(5*2)+(4*4)+(3*5)+(2*8)+(1*7)=102
102 % 10 = 2
So 105245-87-2 is a valid CAS Registry Number.
105245-87-2Relevant academic research and scientific papers
THE MECHANISM FOR THE CONVERSION OF URIC ACID INTO ALLANTOIN AND DEHYDRO-ALLANTOIN. A NEW LOOK AT AN OLD PROBLEM
Poje, M.,Sokolic-Maravic, Lea
, p. 747 - 752 (2007/10/02)
The reaction of uric acids 1 with iodine in alkaline solution yields, on acidification, new dehydroallantoins 11, or normal oxidation products, allantoins 13, depending on whether an excess or a stoichiometric amount of oxidant was used.The structure and regiochemistry of dehydro-allantoins 11 was established by chemical, spectroscopic, and 14C-labelling methods.These experimental results, in combination with other data, generate a new mechanistic scheme for the uricolytic pathway to allantoin, ruling out the intervention of a symmetrical transition state prior to the decarboxylation step.
